Varenicline

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Smoking Cessation

Conditions

Smoking Cessation

Trial Timeline

Nov 1, 2009 → Jul 1, 2010

NCT ID

NCT00889720

About Varenicline

Varenicline is a approved stage product being developed by Pfizer for Smoking Cessation. The current trial status is completed. This product is registered under clinical trial identifier NCT00889720. Target conditions include Smoking Cessation.

What happened to similar drugs?

12 of 20 similar drugs in Smoking Cessation were approved

Approved (12) Terminated (0) Active (8)

🔄Nicotine gum + Placebo gum + Nicotine inhaler + Placebo inhalerJohnson & JohnsonPhase 3

✅Nicotine patch, nicotine inhaler, bupropion + Nicotine patchJohnson & JohnsonApproved

🔄placebo + Varenicline TartaratePfizerPhase 3

✅varenicline + placeboPfizerApproved

🔄varenicline (CP-526,555)PfizerPhase 3

✅placebo + vareniclinePfizerApproved

🔄Varenicline + BupropionPfizerPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04083144	Pre-clinical	Completed	Aug 22, 2019	Dec 30, 2022	Tobacco Use Disorder
NCT03262662	Phase 3	Completed	Oct 1, 2017	Jul 8, 2021	Tobacco Smoking
NCT02854800	Phase 2/3	Completed	Jul 8, 2016	Apr 10, 2017	Smoking Cessation
NCT02202499	Phase 1	Completed	Jul 17, 2014	Jun 14, 2019	Smoking Cessation
NCT01836276	Approved	Completed	Feb 1, 2013	Apr 1, 2017	Smoking Cessation
NCT01632189	Pre-clinical	Completed	Sep 1, 2012	Aug 1, 2015	Nicotine Dependence
NCT01061710	Pre-clinical	Completed	Jul 1, 2010	Feb 1, 2014	Smoking Cessation
NCT01162239	Phase 3	Completed	May 1, 2010	Jun 1, 2016	Nicotine Dependence
NCT01104636	Pre-clinical	Completed	May 1, 2010	Mar 1, 2011	Smoking Cessation
NCT01093365	Phase 2	Completed	Mar 1, 2010	Aug 1, 2016	Schizophrenia
NCT00889720	Approved	Completed	Nov 1, 2009	Jul 1, 2010	Smoking Cessation
NCT00772941	Pre-clinical	Completed	Feb 1, 2009	Dec 1, 2012	Smoking Cessation
NCT00808015	Pre-clinical	Completed	Feb 1, 2009	Jul 1, 2010	Smoking Cessation
NCT00948155	Approved	Completed	Jan 1, 2009	Nov 1, 2010	Nicotine Dependence
NCT00813800	Pre-clinical	Completed	Jan 1, 2009	Feb 1, 2011	Smoking
NCT00794365	Pre-clinical	Completed	Jul 1, 2008	Nov 1, 2009	Smoking Cessation
NCT00669240	Pre-clinical	Completed	Nov 1, 2007	Aug 1, 2009	Smoking Cessation
NCT01290445	Pre-clinical	Completed	Sep 13, 2007	May 1, 2016	Malformations
NCT00483002	Pre-clinical	Completed	Jun 1, 2007	May 1, 2011	Smoking Cessation
NCT00463918	Phase 1	Completed	May 1, 2007	Dec 1, 2007	Smoking Cessation

Competing Products

20 competing products in Smoking Cessation

See all competitors

Product	Company	Stage	Hype Score
Brenipatide + Placebo	Eli Lilly	Phase 2	42
Nicotine + Nicotine + Nicotine	Johnson & Johnson	Phase 2	35
Nicotine replacement therapy + Nicotine replacement therapy	Johnson & Johnson	Phase 2	35
Nicotine Patch + Placebo Patch	Johnson & Johnson	Phase 1	29
Nicotine Patch + Placebo Patch + SLS Comparator Patch	Johnson & Johnson	Phase 1	29
Nicotine + Placebo	Johnson & Johnson	Pre-clinical	26
Nicotine Patch + Nicotine Patch Comparator + Placebo Patch	Johnson & Johnson	Phase 1	29
Nicotine Patch + Placebo Patch + No Patch Control	Johnson & Johnson	Phase 1	29
Nicotine gum + Placebo gum + Nicotine inhaler + Placebo inhaler	Johnson & Johnson	Phase 3	40
Nicotine patch, nicotine inhaler, bupropion + Nicotine patch	Johnson & Johnson	Approved	43
AZD4041 + Placebo	AstraZeneca	Phase 1	29
taranabant	Merck	Phase 2	35
Nicotine replacement therapy	Novartis	Pre-clinical	22
AFQ065	Novartis	Phase 1	29
Liraglutide + Placebo	Novo Nordisk	Phase 2	35
Varenicline	Pfizer	Phase 2	35
placebo + Varenicline Tartarate	Pfizer	Phase 3	40
varenicline + placebo	Pfizer	Approved	39
varenicline (CP-526,555)	Pfizer	Phase 3	40
placebo + varenicline	Pfizer	Approved	43